ProQR Therapeutics (NASDAQ:PRQR) CEO Purchases $261,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) CEO Boer Daniel Anton De bought 150,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was purchased at an average price of $1.74 per share, for a total transaction of $261,000.00. Following the acquisition, the chief executive officer directly owned 300,000 shares of the company’s stock, valued at approximately $522,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Boer Daniel Anton De also recently made the following trade(s):

• On Tuesday, July 7th, Boer Daniel Anton De purchased 150,000 shares of ProQR Therapeutics stock. The shares were purchased at an average price of $1.59 per share, with a total value of $238,500.00.

ProQR Therapeutics Stock Up 4.1%

NASDAQ:PRQR opened at $1.77 on Thursday. The firm has a market capitalization of $186.49 million, a P/E ratio of -3.54 and a beta of 0.04. The company has a fifty day moving average of $1.62 and a 200 day moving average of $1.67. ProQR Therapeutics N.V. has a 52 week low of $1.33 and a 52 week high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The firm had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. As a group, analysts anticipate that ProQR Therapeutics N.V. will post -0.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PRQR shares. JonesTrading reduced their price target on ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Chardan Capital cut their price objective on ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. Wall Street Zen cut ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.33.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds have recently bought and sold shares of the business. Axiom Investment Management LLC purchased a new stake in ProQR Therapeutics in the first quarter worth about $53,000. Bank of America Corp DE lifted its holdings in shares of ProQR Therapeutics by 6.4% during the first quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 11,186 shares during the last quarter. Walleye Capital LLC lifted its holdings in shares of ProQR Therapeutics by 2.7% during the first quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock valued at $984,000 after purchasing an additional 15,744 shares during the last quarter. Invesco Ltd. bought a new stake in shares of ProQR Therapeutics in the 4th quarter worth approximately $51,000. Finally, XTX Topco Ltd boosted its position in shares of ProQR Therapeutics by 1,057.4% in the 4th quarter. XTX Topco Ltd now owns 117,900 shares of the biopharmaceutical company’s stock worth $238,000 after purchasing an additional 107,713 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.